Consun Pharmaceutical Group Limited (1681.HK) Stock Analysis

Consun Pharmaceutical Group Limited (1681.HK) is a research-driven Chinese pharmaceutical company focused on traditional Chinese medicines and medical contrast media. Its 143-product portfolio comprises 62 Chinese patent medicines and 81 chemical drugs, with nephrology products providing the principal growth and profit engine. UCG/Niaoduqing and Yishen Huashi Granules benefit from clinical evidence, hospital prescribing integration, and a substantial cost advantage over dialysis. **FY2025 revenue rose 15.2% to RMB 3.42 billion and attributable net income increased 18.4% to RMB 1.08 billion**, while gross margin reached approximately 78.0%, net margin 31.5%, ROE 25.0%, and operating cash flow RMB 1.21 billion. The balance sheet held approximately RMB 4.38 billion of cash, over 90% of net assets, with minimal debt. At HKD 13.58, the shares trade at approximately 9.34x P/E and under 6x ex-cash P/E, alongside a 5.15% trailing dividend yield and 52% payout ratio. The near-term setup is supported by a HKD 200 million buyback, interim results, Hong Kong Stock Connect flows, and potential pipeline and Shanghai Huamao catalysts. Three covering firms have a consensus 12-month target of HKD 23.54.